drugset / Trial / NCT05023525
A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers
Phase 1
Completed
32 enrolled
Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical(Australia) Pty Ltd. · collab
RandomizedParallel-groupDouble-blindOther
Summary
This is a Phase I, single-dose escalation clinical trial for HSK31858 conducted in healthy volunteers. The safety, tolerability, and pharmacokinetics of HSK31858 tablet in healthy volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design.
Timeline
- Start
- 2021-10-28
- Primary completion
- 2022-04-19
- Completion
- 2022-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK31858 | Unknown | 5 mg | — |
Indications
No indication recorded.